You are here

FDA Approves Reversal Agent for Pradaxa

Praxbind is the first FDA-approved reversal agent for a novel oral anticoagulant

Idarucizumab (Praxbind, Boehringer Ingelheim) has received FDA approval for patients treated with dabigatran etexilate (Pradaxa, Boehringer Igelheim) when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery, for urgent procedures, or in life-threatening or uncontrolled bleeding. The product had been granted breakthrough therapy and priority review designations  and  was approved under an accelerated approval pathway.

Approval was based on results of studies and an interim analysis that found that idarucizumab’s reversal effects were evident within minutes after administration of 5 g of the reversal agent.

Boehringer Ingelheim is continuing to evaluate the product  in RE-VERSE AD, a phase III global study that includes patients taking dabigatran etexilate who have uncontrolled bleeding or require emergency procedures. The study, the first of its kind in patients, has been under way since May 2014, enrolling patients in more than 35 countries.

Idarucizumab is a humanized antibody fragment designed as a specific reversal agent to dabigatran. It binds specifically to dabigatran molecules only, neutralizing their anticoagulant effect without interfering with the coagulation cascade.

Currently approved indications for dabigatran are prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and a risk factor for stroke, primary prevention of venous thromboembolic events in patients undergoing elective total hip replacement surgery or total knee replacement surgery, and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and recurrent PE in adults.

Source: Boeringer Ingelheim, October 19, 2015.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time